Characterizing the Genomic Profile in High-Grade Gliomas: From Tumor Core to Peritumoral Brain Zone, Passing through Glioma-Derived Tumorspheres
Martina Giambra,
Eleonora Messuti,
Andrea Di Cristofori,
Clarissa Cavandoli,
Raffaele Bruno,
Raffaella Buonanno,
Matilde Marzorati,
Melissa Zambuto,
Virginia Rodriguez-Menendez,
Serena Redaelli,
Carlo Giussani,
Angela Bentivegna
Affiliations
Martina Giambra
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Eleonora Messuti
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Andrea Di Cristofori
Neurosurgery Unit, Department of Neuroscience, S. Gerardo Hospital, 20900 Monza, Italy
Clarissa Cavandoli
Neurosurgery Unit, Department of Neuroscience, S. Gerardo Hospital, 20900 Monza, Italy
Raffaele Bruno
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Raffaella Buonanno
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Matilde Marzorati
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Melissa Zambuto
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Virginia Rodriguez-Menendez
NeuroMI, Milan Center of Neuroscience, Department of Neurology and Neuroscience, University of Milano-Bicocca, San Gerardo Hospital, Via Pergolesi, 20900 Monza, Italy
Serena Redaelli
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Carlo Giussani
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Angela Bentivegna
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Glioblastoma is an extremely heterogeneous disease. Treatment failure and tumor recurrence primarily reflect the presence in the tumor core (TC) of the glioma stem cells (GSCs), and secondly the contribution, still to be defined, of the peritumoral brain zone (PBZ). Using the array-CGH platform, we deepened the genomic knowledge about the different components of GBM and we identified new specific biomarkers useful for new therapies. We firstly investigated the genomic profile of 20 TCs of GBM; then, for 14 cases and 7 cases, respectively, we compared these genomic profiles with those of the related GSC cultures and PBZ biopsies. The analysis on 20 TCs confirmed the intertumoral heterogeneity and a high percentage of copy number alterations (CNAs) in GBM canonical pathways. Comparing the genomic profiles of 14 TC-GSC pairs, we evidenced a robust similarity among the two samples of each patient. The shared imbalanced genes are related to the development and progression of cancer and in metabolic pathways, as shown by bioinformatic analysis using DAVID. Finally, the comparison between 7 TC-PBZ pairs leads to the identification of PBZ-unique alterations that require further investigation.